Partial
Needs Revision
Patient Risk:
Medium
Summary
Many hypotension-related claims are partially supported by the label (sections 5.3 and 6.1), but there is a direct contradiction regarding ACE inhibitors, and multiple other claims are not supported or not explicitly stated in the provided label text.
Category Scores
Accurate Statements
Entresto (sacubitril/valsartan) is used to treat heart failure.
Supported by provided label content reference: Indications and Usage (1 INDICATIONS AND USAGE).
Entresto can lead to low blood pressure in some patients.
Supported by 5.3 Hypotension stating ENTRESTO lowers blood pressure and may cause symptomatic hypotension.
Low blood pressure is a common side effect of Entresto.
Partially supported by 6.1 Clinical Trials Experience (Table 3 shows Hypotension 18% in PARADIGM-HF).
Low blood pressure occurs in about 20% of patients who take Entresto.
Partially supported by 6.1 Clinical Trials Experience (Table 3: Hypotension 18% in PARADIGM-HF).
Symptoms of low blood pressure while on Entresto can include dizziness.
Partially supported by 6.1 Clinical Trials Experience (Table 3 includes Dizziness 6%); label does not explicitly phrase it as a symptom of hypotension.
Orthostatic hypotension can occur in some cases while on Entresto.
Partially supported by 6.1 Clinical Trials Experience (Orthostasis reported 2.1%).
Orthostasis can be associated with falls.
Falls reported 1.9% in 6.1 Clinical Trials Experience; label does not explicitly link falls to orthostatic hypotension.
Entresto should be monitored with blood pressure adjustment of dose or addition of other medications as needed to maintain safe blood pressure levels.
Partially supported by 5.3 Hypotension: consider dose adjustment of diuretics and concomitant antihypertensive drugs; reduce dosage or temporarily discontinue if hypotension persists.
Entresto can interact with other medications such as diuretics to potentiate low blood pressure.
Partially supported by 5.3 Hypotension: greater risk in volume- and/or salt-depleted patients (e.g., high doses of diuretics).
Dehydration and electrolyte imbalances can increase the risk of low blood pressure while taking Entresto.
Partially supported by 5.3 Hypotension regarding volume- and/or salt-depleted patients at greater risk (label text provided does not explicitly mention dehydration/electrolyte imbalances as a cause).
The risk of low blood pressure with Entresto is higher when combined with other blood pressure-lowering medications.
Partially supported by 5.3 Hypotension: greater risk in certain patients and consideration of dose adjustment of concomitant antihypertensive drugs.
Orthostatic hypotension can occur in some cases while on Entresto.
Partially supported by 6.1 Clinical Trials Experience (Orthostasis reported 2.1%).
Unsupported Statements
Entresto contains sacubitril, which blocks the effects of a chemical that causes blood vessels to constrict.
No support in the provided label sections for this mechanism statement.
Entresto contains valsartan, which is an ARB that relaxes blood vessels.
No support in the provided label sections for this ARB/vasodilation mechanism phrasing.
The risk of low blood pressure with Entresto is higher at higher doses.
Not explicitly supported in the provided label text (5.3 and 6.1 excerpts do not state dose-dependent hypotension risk).
Symptoms of low blood pressure while on Entresto can include lightheadedness.
Not explicitly supported in the provided label text.
Symptoms of low blood pressure while on Entresto can include fainting.
Not explicitly supported in the provided label text.
Patients with pre-existing low blood pressure may still be able to take Entresto safely.
Not explicitly supported in the provided label text.
Entresto can interact with other medications such as beta blockers to potentiate low blood pressure.
Not supported in the provided label text.
Dehydration and electrolyte imbalances can occur while taking Entresto.
Not supported in the provided label text.
Long-term use of Entresto can lead to an increased risk of low blood pressure.
Not supported in the provided label text.
The increased risk of low blood pressure with long-term Entresto use is especially in patients with pre-existing hypertension.
Not supported in the provided label text.
Contradictions
High
AI Statement
Entresto can interact with other medications such as ACE inhibitors to potentiate low blood pressure.
Label Reference
7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone System (concomitant use with an ACE inhibitor is contraindicated)
Important Omissions
No user claim addressed the contraindication/washout requirement when switching from ACE inhibitors (36-hour washout) or the specific contraindicated co-use with ACE inhibitors beyond the contradicted interaction framing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
A directly contradicted claim about ACE inhibitor coadministration conflicts with a contraindication, which is a high-severity safety issue. Additional unsupported symptom/mechanism and risk-modifier claims may mislead interpretation of label guidance on hypotension.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Direct contradiction: framing ACE inhibitors as an interaction that potentiates low blood pressure conflicts with the label contraindication for concomitant ACE inhibitor use.
Suggested Improvement
Re-state ACE inhibitor coadministration as contraindicated (and include washout guidance when switching from an ACE inhibitor) instead of describing it as a mere interaction; remove or qualify claims not explicitly supported in the provided label text.